Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company, has announced the appointment of Professor John Oxford as chair of a newly established Advisory Board which will initially focus on guiding the company on the provision of solutions to the current coronavirus outbreak.
Professor Oxford is a professor at Queen Mary's University London and one of the world's leading experts on global diseases such as influenza, including bird flu, SARS, MERS and coronavirus.
READ: Open Orphan gets £5mln from City fundraiser that will be used to accelerate growth post-merger
The AIM-listed firm - which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe's only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London - said the Advisory Board has been established to help the company support product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the coronavirus in 2020.
The group said Professor Oxford will chair the Advisory Board alongside Professor Brendan Buckley, a director of Open Orphan.
At the end of last year, Open Orphan launched an all-share merger with fellow AIM-listed pharma group hVIVO.